Gene Therapy...

Since 1998, when 18-year-old Jesse Gelsinger died in a clinical trial at the University of Pennsylvania, the news on gene therapy hasn't gotten much better.

May 9, 2005

<p/>

David Mack/Photo Researchers, Inc.

Since 1998, when 18-year-old Jesse Gelsinger died in a clinical trial at the University of Pennsylvania, the news on gene therapy hasn't gotten much better. In a recent trial, three children developed leukemia almost certainly brought on by their treatment for X-linked severe combined immunodeficiency (X-SCID). So it's no surprise that there's some trepidation on the part of investors when it comes to companies exploring new gene-altering techniques – the subject of the opening piece of our special feature section on gene therapy.

Still, it's an inescapable fact that gene therapy saved the lives of other children in that same X-SCID trial. Those kinds of results are encouraging for people like Carl June, director of translational research at the Abramson Cancer Center at the University of Pennsylvania, who writes on why cancer gene therapy will be both a medical and financial success. Finally, this issue's Hot Papers recount the discovery of the misdirected transgene responsible for leukemia in two of the affected children and the warning signs that indicate that some retroviral vectors are prone to cause such problems. There's clearly a long road ahead for gene therapy, but it's certainly not the dead end it may have seemed in the past.

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Sequencing Reveals Genomic Diversity of the Human Brain
  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech